Abbott Libre 3 Class Action Lawsuit Claims CGM Defects Could Result in Serious Injury

Recalled continuous glucose monitoring device was linked to 736 reports of serious injuries and at least seven deaths due to inaccurate readings.

In the wake of an Abbott Freestyle Libre 3 continuous glucose monitor recall late last year, the manufacturer now faces a class action lawsuit claiming it concealed critical, and ultimately deadly, manufacturing defects from federal regulators, the medical community and patients.

Continuous glucose monitors (CGMs) are small devices worn on the upper arm that continuously track blood sugar levels, a critical tool for people with diabetes who rely on real-time data to avoid dangerous highs and lows. By showing current levels and trends, the sensors help users adjust medication, food intake and daily activity.

The Freestyle Libre 3 recall was announced on November 24, 2025, following more than 700 reports of serious health consequences, including at least seven deaths linked to complications caused by false readings. Internal testing of FreeStyle Libre 3 units found that some may generate undetected false lows for extended periods. This can mislead users into taking insulin they do not need, increasing the risk of severe hypoglycemia, confusion, loss of consciousness and other life-threatening complications.

The recall impacted approximately 3 million Abbott FreeStyle Libre 3 and Libre 3 Plus sensors in the U.S., about half of which are estimated to have already expired or been used.

On January 1, plaintiffs Christopher Taylor and Krystal Chambers filed a complaint (PDF) in the U.S. District Court for the Northern District of California against Abbott Diabetes Care Inc. and Abbott Laboratories, alleging the companies hid manufacturing problems while simultaneously making false and misleading statements about the safety and effectiveness of the recalled glucose sensors.

In the lawsuit, neither Taylor nor Chambers indicate they suffered physical injuries from the recalled Freestyle Libre 3. However, they seek class action status for themselves and other similarly situated consumers who purchased the device, believing they were buying a safe and effective glucose sensor.

The plaintiffs note that this is particularly dangerous for diabetics, who can be left in life-threatening situations if given inaccurate glucose data. Taylor, of Tennessee, is a type 1 diabetic who began using the sensors in 2024. Chambers, of Mississippi, also began using the devices beginning in 2024, and is a type 2 diabetic.

Both Taylor and Chambers indicate they received dangerously inaccurate glucose readings from the devices when compared to the results of traditional fingerstick measurements, as well as failed alerts.

According to the complaint, the problem tracks back to at least one defective production line that led to the sensors providing incorrect low glucose readings.

“The defect caused the affected sensors to falsely indicate hypoglycemia (low blood sugar) when patients’ actual glucose levels were normal or elevated. This manufacturing deviation created a systematic pattern of inaccurate readings in the affected sensors that undermined their intended function of continuous glucose monitoring.”

– Christopher Taylor et al. v. Abbott Diabetes Care Inc. et al

Taylor and Chambers indicate Abbott knew or should have known of this problem since at least 2024, after identifying the issue through its own internal testing. Despite having this information, the lawsuit claims the manufacturer sat on it, refusing to issue warnings or recalls for more than a year while placing profits over patient safety.

In addition, the class action lawsuit alleges that even after Abbott reported it had received 736 serious injury reports as of November 14, it waited another 10 days to issue a public correction notice, which deprived users of further opportunities to switch to a safer monitoring system.

Plaintiffs allege Abbott has a history of concealing such problems, particularly with its Freestyle CGMs, noting that it had to issue a similar Freestyle recall in July 2024 due to inaccurate glucose readings.

The lawsuit presents claims of fraudulent omission, unjust enrichment, breach of unfair competition law, violation of the Mississippi Consumer Protection Act and the Tennessee Consumer Protection Act. The plaintiffs seek both compensatory and punitive damages.

FreeStyle Libre 3 Lawsuits

Following the recall, attorneys are now investigating FreeStyle Libre 3 lawsuits for individuals and families who suffered injuries or wrongful death caused by incorrectly low glucose readings. 

You may qualify for a Libre 3 recall lawsuit if you or a loved one used a recalled FreeStyle Libre 3 or Libre 3 Plus sensor and suffered serious injuries after relying on inaccurate glucose readings, including:

• Wrongful Death
• Severe hypoglycemia
• Seizures
• Confusion or altered mental state
• Loss of consciousness
• Diabetic ketoacidosis
• Other acute metabolic emergencies
• Emergency medical treatment or hospitalization

To determine whether you or a family member may qualify for a FreeStyle Libre 3 lawsuit, submit your information for a free case evaluation. An attorney can review your case, explain your legal rights, and pursue a claim if eligible.

Sign up for more legal news that could affect you or your family.